Seeking Alpha

Alkermes (ALKS +1.1%) gets a boost when UBS upgrades shares to a Buy from Neutral. Analyst Ami...

Alkermes (ALKS +1.1%) gets a boost when UBS upgrades shares to a Buy from Neutral. Analyst Ami Fadia sees global sales exceeding $4B by 2016, and sees synergy from the pending buyout of Elan Drug Technologies, a unit of Elan (ELN +2.9%).
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs